Cancer treatment protects one thing while it weakens another.
Your patients are surviving cancer in numbers that would have been unthinkable a generation ago. But many of the therapies that get them there change bone quality long before they change bone density.
That’s the danger. By the time a density scan registers the loss, the tissue has often been fragile for months. The damage stays invisible until something breaks.
Treatment-induced bone loss hides from density
The mechanism differs by therapy, but the pattern is the same: bone becomes more fragile before, or without, a proportional drop in density.
- Aromatase inhibitors accelerate bone loss in breast cancer patients by removing estrogen’s protective effect on the skeleton
- Androgen deprivation therapy does the same in prostate cancer, and fracture is a recognized complication
- Glucocorticoids, used across oncology for nausea, inflammation, and as part of many regimens, suppress bone formation and impair mineralization — with measurable deterioration in bone material strength documented within 7 weeks of starting treatment, before any change in density
- Chemotherapy affects bone through direct toxicity, hypogonadism, and reduced activity
By the time a T-score reflects the damage, the patient may already have been fragile for months.
What density can’t tell you
Cancer therapies don’t just thin bone. They degrade its quality — and quality is what determines whether it breaks. That damage often shows up in the tissue before it shows up on a scan. Density can still read reassuringly normal while the bone underneath is already weakening. Some cancer therapies degrade bone material strength before density changes: glucocorticoids lowered BMSi within 7 weeks in one study, before any density change. BoneScore measures BMSi chairside, without radiation.Move at the pace of treatment
Oncology moves in months, not years. DXA’s two-to-five-year interval isn’t built for that — and every repeat scan adds to a radiation burden your patients are already carrying from staging, surveillance, and therapy.
OsteoProbe measures bone quality at the tibia, chairside, with no radiation. Take a baseline before therapy, measure again during it, and repeat as often as makes clinical sense — so bone quality becomes something you can track.
In one study, BMSi changed measurably within 7 weeks of starting a bone-affecting therapy. Density wouldn’t have shown it for years.
Adding it to your practice
- Performed by your RN, chairside
- No radiation — a meaningful advantage in patients already managing cumulative exposure
- Well-tolerated — pain scores at or below 1 of 10 NRS
- CPT III code 0547T issued; coverage currently case-by-case